Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018	Feb. 28, 2019	Feb. 28, 2018
Income Statement [Abstract]
Revenues	$ 2,200,410	$ 2,145,919	$ 4,512,032	$ 4,399,656
Cost of revenues	1,320,740	1,307,596	2,748,823	2,715,289
Gross profit	879,670	838,323	1,763,209	1,684,367
Operating expenses:
Selling expenses	4,016	30,601	29,239	68,740
General and administrative expenses	954,341	1,934,479	2,028,009	2,914,754
Total operating expenses	958,357	1,965,080	2,057,248	2,983,494
Loss from operations	(78,687)	(1,126,757)	(294,039)	(1,299,127)
Non operating income (expense)
Interest income	4,294	160	9,383	211
Interest expense	(48,587)	(304,132)	(94,908)	(438,285)
Total other income (expense)	(44,293)	(303,972)	(85,525)	(438,074)
Loss before income taxes	(122,980)	(1,430,729)	(379,564)	(1,737,201)
Income tax expense		(54,216)
Net loss	(122,980)	(1,376,513)	(379,564)	(1,737,201)
Net loss attributed to noncontrolling interest	(3,479)	(1,956)	(8,647)	(5,356)
Net loss attributed to Novo Integrated Sciences, Inc.	(119,501)	(1,374,557)	(370,917)	(1,731,845)
Comprehensive loss:
Net loss	(122,980)	(1,376,513)	(379,564)	(1,737,201)
Foreign currency translation gain (loss)	27,765	(211,528)	25,980	(87,341)
Comprehensive loss	$ (95,215)	$ (1,588,041)	$ (353,584)	$ (1,824,542)
Weighted average common shares outstanding - basic and diluted	214,281,342	206,091,162	211,094,982	203,953,457
Net loss per common share - basic and diluted	$ (0.00)	$ (0.01)	$ (0.00)	$ (0.01)